middle.news
Argenica Advances Late-Stage Stroke Trial with Clean FDA Safety Data and $6.35M Cash
9:18am on Friday 24th of July, 2026 AEST
•
Biotechnology
Read Story
Argenica Advances Late-Stage Stroke Trial with Clean FDA Safety Data and $6.35M Cash
9:18am on Friday 24th of July, 2026 AEST
Key Points
Preparations underway for late-stage acute ischaemic stroke trial
FDA-requested safety assays completed with favourable results
WHO confirms xaranetide as international nonproprietary name
Preclinical concussion study shows significant neuroprotection
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE